Table 3.
Clinical trial of resveratrol in the treatment of diabetes mellitus and its cardiovascular complications.
| Identifier No. | Type | Dose/Dosing Method/Period | Phase | Sex | Number Enrolled | Outcome Measures |
|---|---|---|---|---|---|---|
| NCT01038089 | T2DM | RES (90 mg/d and 270 mg/d for 2 weeks) | Not Applicable | All | 20 | Brachial artery flow-mediated dilation Blood markers of inflammation, oxidative stress, insulin resistance |
| NCT01677611 | T2DM | RES (3 g/d for 12 weeks) | Phase 1 | Male | 10 | SIRT1 expression Skeletal muscle AMPK expression Skeletal muscle p-AMPK expression |
| NCT01881347 | T2DM | RES (100 mg/d for 2 weeks and then 300 mg/d for 2 weeks) | Not Applicable | All | 54 | Change from baseline in Brachial artery flow-mediated dilation Change from Baseline in Fingertip peripheral arterial tonometry Change from Baseline in Carotid femoral pulse wave velocity Change from Baseline in Reactive hyperemia |
| NCT01638780 | T2DM | RES (150 mg/kg/d for 30 days) | Not Applicable | Male | 24 | insulin sensitivity (overall, muscle- and liver-specific) muscle mitochondrial oxidative capacity intramyocellular lipid content |
| NCT04449198 | T1DM | RES (500 mg, twice a day for 12 weeks) | Early Phase 1 | All | 24 | Change in AUC for ET-1 + BQ-123 Skeletal Muscle Mitochondrial Function Change in Percentage FMD |
| NCT03436992 | T1DM | RES (1500 mg for 3 months) | Not Applicable | All | 198 | Change in FMD |
| NCT03762096 | T2DM+CAD | RES (1 g, twice a day for 6 weeks) | Not Applicable | All | 40 | Change in endothelial function Effects of resveratrol on caveolar function Effects of resveratrol on molecular signaling |
| NCT01354977 | T2DM+ Insulin Resistance | RES (1000 mg, twice a day for 4 weeks) | Phase 2 | All | 20 | Peripheral Insulin Sensitivity (RD) Measured by the Change in Glucose Rates of Disappearance with Resveratrol or Placebo at Baseline and at 4 weeks. EGP, With Resveratrol or Placebo at Baseline and at 4 weeks. Effects of Resveratrol on Skeletal Muscle Mitochondrial Numbers |
| NCT02244879 | T2DM+ Inflammation+Insulin Resistance | RES (40 mg/d and 500 mg/d for 6 months) | Phase 3 | All | 192 | CRP Metabolic and oxidative markers |
Website: ClinicalTrials.gov (accessed on 19 May 2022). AUC: Area under the curve; CAD: Coronary artery disease; CRP: C reactive protein; EGP: Endogenous glucose production; ET-1: Endothelin 1; FMD: Flow-mediated dilation; p-AMPK: phosphorylated-AMPK-Thr172; RES: Resveratrol; SIRT1: Sirtuin 1; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus.